Medicine. The need for a global HIV vaccine enterprise

Science. 2003 Jun 27;300(5628):2036-9. doi: 10.1126/science.1086916.


A new collaborative model of research is needed to increase resources, to prioritize the R (ii) to increase the pace, reduce the overlap, and more systematically explore the elements of and delivery systems for vaccines; (iii) to use common standards for the prompt comparative testing of vaccine candidates; (iv) to expand resources for manufacturing vaccine candidates to speed their use in human trials; and (v) to increase the capacity for international clinical trials and to focus this effort toward quickly measuring the effectiveness of vaccine protection as prototype vaccine candidates are identified.

MeSH terms

  • AIDS Vaccines* / administration & dosage
  • AIDS Vaccines* / economics
  • AIDS Vaccines* / immunology
  • Academies and Institutes / economics
  • Academies and Institutes / organization & administration
  • Biotechnology / economics
  • Clinical Trials as Topic / standards
  • Drug Design
  • Drug Evaluation, Preclinical / standards
  • Drug Industry / economics
  • Financial Support
  • Global Health*
  • HIV Infections / prevention & control*
  • HIV-1 / immunology*
  • Humans
  • Intellectual Property
  • International Cooperation
  • Multicenter Studies as Topic
  • Private Sector
  • Public Policy*
  • Public Sector
  • Research Support as Topic
  • Vaccination


  • AIDS Vaccines